MindWalk, a bio-native AI research and biotherapeutics technology company that combines in silico and wet lab operations for biologic discovery and development, announced its financial results for the second quarter of fiscal 2026 and provided updates on its AI-focused asset pipeline and strategic initiatives. MindWalk operates a proprietary bio-native AI platform based on patented HYFT models , evolutionarily shaped subsequence codes that link sequence, structure, and function. These models underpin LensAI, a software platform that harmonizes and analyzes diverse biological data to deliver actionable insights.

Health Technology Insights: Adtalem Completes $150Million Buyback, Approves $750Million Program

Key financial highlights (quarter ended October 31, 2025)

  • Revenue: $4.1 million, up 54% year over year and 30% sequentially, thanks to improved project revenue and better utilization of project and platform revenue streams.
  • Gross margin: 65%, up from the previous quarter (51%). Gross profit increased significantly, by 94% year-over-year, to $2.7 million, as leverage on fixed costs and higher-margin projects improved profitability.
  • The operating loss, excluding depreciation and non-recurring items, improved significantly, falling from $4.1 million last year to $2.8 million.
  • Adjusted EBITDA: The loss narrowed to $2.4 million, compared to $2.6 million in the prior year period.
  • Liquidity: Cash and cash equivalents of $16.5 million at the end of the quarter (including proceeds from the sale of the company’s former operations in the Netherlands), providing flexibility to invest in platform expansion and internal pipeline programs.

Strategic and operational highlights

Major portfolio advances

  • GLP1 Program and Longevity: MindWalk has advanced its AI-designed GLP1 receptor agonist program, achieving superior receptor activation compared to semaglutide in in vitro assays . The company has also identified a companion pathway linked to the biology of aging and is developing a dual-pathway regimen targeting metabolic control and longevity.
  • Universal Dengue Vaccination Initiative: Using its LensAI platform, which leverages HYFT models to analyze multi-omics data, MindWalk has identified a highly conserved discontinuous epitope shared among the four dengue virus serotypes. Preclinical planning is underway and expected to be completed early next quarter, and a collaborator has been selected to advance this program.

New Brand Identity and Leadership Expansion:


The company completed its rebranding as MindWalk and consolidated its operating units under the ticker symbol HYFT Nasdaq. During the quarter, MindWalk welcomed Scott Areglado as Chief Financial Officer and Dr. Thomas Lynch as Chief Commercial Officer.

Health Technology Insights: Chai Discovery Announces $130 Million Series B To Transform Molecular Discovery

Strategic divestiture:


MindWalk has completed the sale of its Dutch operations, generating net proceeds of $14.3 million. The divestiture allows the company to allocate resources to its bio-native AI initiatives and high-value wet lab programs aligned with LensAI.

MindWalk has begun structuring its AI asset pipeline


by establishing a Cayman Islands company with the law firm Walkers to house separate portfolios for each AI-focused program. Under this structure, the assets and liabilities of each program will be ring-fenced, allowing investors to participate directly in individual portfolios rather than through a publicly traded company. Management has received strong expressions of interest from potential investors and will provide further details as the structure is finalized.


MindWalk plans to release a press release through national media outlets on the first day of the JP Morgan Healthcare conference, January 12. This update will include new information on the company’s AI asset portfolio and its capital and partnership strategy .

Health Technology Insights: Algia Pharma Advances Non-Opioid Pain Treatment to Phase 2

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com

Source- businesswire